ScandiBio Therapeutics
Share:
Subscribe:

news.cision.com/
ScandiBio Therapeutics/
ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease/
Mathias Uhlén foto Gustav Ceder

Mathias Uhlén foto Gustav Ceder

Tue, Nov 04, 2025 08:25 CET

Medium resolution

Original resolution

Subscribe

©Cision

Privacy statement | Cookies | About | Content Policy | Contact

©Cision Privacy statement Cookies About Content Policy Contact